We are live on ! Find out more
ODTX

Odyssey Therapeutics
ODTX

50 hedge funds and large institutions have $384M invested in Odyssey Therapeutics in 2026 Q2 according to their latest regulatory filings, with 50 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

42.78% more ownership

Funds ownership: 0% → 42.78% (+43%)

Holders
50
Holders Change
+50
Holders Change %
–
% of All Funds
0.61%
Holding in Top 10
5
Holding in Top 10 Change
+5
Holding in Top 10 Change %
% of All Funds
0.06%
New
50
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SOCM
SR One Capital Management
Pennsylvania
+$66.5M
2
LMC
Lightspeed Management Company
California
+$63.3M
3
S
Sanofi
France
+$34.9M
4
SCV
Sands Capital Ventures
Virginia
+$15.3M
5
HA
HHLR Advisors
Cayman Islands
+$14.6M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$2.93M +$2.75M +156,602 New
Goldman Sachs
27
Goldman Sachs
New York
$2.48M +$2.33M +132,801 New
Charles Schwab
28
Charles Schwab
California
$1.9M +$1.78M +101,531 New
Vanguard Fiduciary Trust
29
Vanguard Fiduciary Trust
Pennsylvania
$1.89M +$1.77M +100,905 New
UBS Group
30
UBS Group
Switzerland
$1.29M +$1.21M +68,758 New
Ensign Peak Advisors
31
Ensign Peak Advisors
Utah
$1.21M +$1.13M +64,621 New
SGM
32
Seven Grand Managers
New York
$936K +$877K +50,000 New
EP
33
Eversept Partners
New York
$929K +$871K +49,658 New
Northern Trust
34
Northern Trust
Illinois
$647K +$607K +34,588 New
Manulife (Manufacturers Life Insurance)
35
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$601K +$563K +32,125 New
TD Asset Management
36
TD Asset Management
Ontario, Canada
$545K +$511K +29,134 New
JP Morgan Chase
37
JP Morgan Chase
New York
$525K +$487K +27,787 New
GCM
38
Ghisallo Capital Management
Massachusetts
$468K +$438K +25,000 New
BGM
39
Burkehill Global Management
New York
$374K +$351K +20,000 New
D.E. Shaw & Co
40
D.E. Shaw & Co
New York
$371K +$348K +19,848 New
XT
41
XTX Topco
Cayman Islands
$310K +$290K +16,552 New
Vanguard Portfolio Management
42
Vanguard Portfolio Management
Pennsylvania
$256K +$240K +13,685 New
Vanguard Global Advisers
43
Vanguard Global Advisers
Pennsylvania
$149K +$139K +7,948 New
OFM
44
Omega Fund Management
Massachusetts
$54.1K +$50.7K +2,893 New
Legal & General Group
45
Legal & General Group
United Kingdom
$37.3K +$35.1K +2,000 New
Wells Fargo
46
Wells Fargo
California
$33.6K +$31.5K +1,795 New
Morgan Stanley
47
Morgan Stanley
New York
$33.2K +$31.1K +1,772 New
Barclays
48
Barclays
United Kingdom
$27.3K +$25.6K +1,459 New
Citigroup
49
Citigroup
New York
$9.56K +$8.96K +511 New
TRCT
50
Tower Research Capital (TRC)
New York
$3.61K +$3.38K +193 New
1
2

ODTX Hedge Fund Activity: Q2 2026 in Review

50 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in Odyssey Therapeutics (ODTX) for Q2 2026, worth a combined $384M.

Buyers outnumbered sellers: 50 funds opened new ODTX positions and 0 closed out — a net gain of 50 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was SR One Capital Management, opening a new position worth an estimated $66.5M.

  • 50 institutional investors held Odyssey Therapeutics (ODTX) as of Q2 2026, up from 0 in Q1 2026.
  • Funds reported $384M of Odyssey Therapeutics stock for Q2 2026.
  • 50 funds opened new Odyssey Therapeutics positions in Q2 2026 and 0 closed out, a net change of +50 holders.
  • The largest Odyssey Therapeutics buyer in Q2 2026 was SR One Capital Management, an estimated $66.5M added.

Based on aggregated 13F filings for Q2 2026.